Zhao Jianguo, Xiong Jianping
Department of Medical Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, China.
Department of Medical Oncology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):42-7. doi: 10.3779/j.issn.1009-3419.2015.01.07.
Adenocarcinoma and squamous cell carcinoma are the most common histological types of non-small cell lung cancer (NSCLC). Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. With next-generation sequencing (NGS) which having multiple and high-throughput genotyping is wildly used and promoted, make the detection of patients gene composition from a tiny tumor biopsy specimens become possible, initiate the clinical studies based on the genetic characteristics, and promote the progress of molecular typing in NSCLC. So far, about 60% of lung adenocarcinoma has been found harbouring driver oncogenes, the rate of lung squamous cell carcinoma driven genes detection has gradually improved, in which epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor 1 (FGFR1), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) and so on plays important roles. The currently effective targeted therapies is mainly used against EGFR, ALK, etc. In this review, we will report the mainly advances on some latest driver mutations of NSCLC.
腺癌和鳞状细胞癌是非小细胞肺癌(NSCLC)最常见的组织学类型。几种分子改变已被定义为负责恶性肿瘤起始和维持的“驱动癌基因”。随着具有多重和高通量基因分型的下一代测序(NGS)被广泛应用和推广,使得从微小肿瘤活检标本中检测患者基因组成成为可能,启动基于遗传特征的临床研究,并推动NSCLC分子分型的进展。到目前为止,已发现约60%的肺腺癌含有驱动癌基因,肺鳞状细胞癌驱动基因的检测率也在逐渐提高,其中表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)、成纤维细胞生长因子受体1(FGFR1)、磷脂酰肌醇3-激酶催化亚基α(PIK3CA)等发挥着重要作用。目前有效的靶向治疗主要针对EGFR、ALK等。在本综述中,我们将报告NSCLC一些最新驱动突变的主要进展。